Abstract:Objective The Endocrine Society recommends a postpartum fasting blood glucose (FBG) be performed for patients with gestational diabetes mellitus (GDM) prior to hospital discharge to screen for ongoing hyperglycemia. There are limited data, however, on whether an FBG can screen for glucose intolerance and if it correlates with the gold standard 4- to 12-week 2-hour oral glucose tolerance test (OGTT). Our objective was to evaluate if FBG correlates with the gold standard 2-hour OGTT. Study Design This retrospective cohort study of patients with GDM who delivered >20 weeks' gestation at two urban centers from January 2017 to December 2020 included those who completed both a postpartum FBG prior to discharge and a 2-hour 75-g OGTT within 1 year of delivery. Abnormal 2-hour OGTT was defined as fasting value ≥100 mg/dL and/or 2-hour value ≥140 mg/dL. We evaluated test characteristics (e.g., sensitivity, specificity) of postpartum FBG cut-offs to predict an abnormal 2-hour OGTT result. Results A total of 235 patients met inclusion criteria, of which 63% were diet-controlled and 37% required medical management. FBG ranged from 64 to 134 mg/dL, with 6/235 (2.6%) with values ≥126 mg/dL. A total of 39/235 (16.6%) of patients had an abnormal 2-hour OGTT. Overall, area under the curve for FBG predicting abnormal 2-hour OGTT was 0.65. Traditionally considered high cut-offs (≥126 mg/dL) for predicting persistent impaired glucose intolerance demonstrated poor positive predictive value (PPV; 90%). A postpartum FBG of 88 mg/dL was determined to be the optimal cut-off for FBG with NPV = 92.4% (Youden index = 0.34). In this dataset, if FBG ≥ 88 mg/dL was used to determine if 2-hour OGTT was required, almost half of GDM patients could avoid further glucose tolerance testing. Conclusion While previously thought of as best utilized for its PPV, the FBG may be best used for its NPV. In our study, clinical application of an FBG < 88 mg/dL was highly correlative with a normal 2-hour OGTT. Key Points Screening for postpartum glucose intolerance is essential for gestational diabetes. A promising initiative includes offering screening tests while in the hospital, including an FBG. Application of a postpartum FBG < 88 mg/dL is highly correlative with a normal 2-hour OGTT. Received: 03 July 2024 Accepted: 17 September 2024 Accepted Manuscript online: 17 September 2024 Article published online: 01 October 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

Evaluation of postpartum dysglycemia by serum glycosylated hemoglobin in patients with gestational diabetes mellitus: a national data analysis

Gestational diabetes mellitus – Can we do better with postpartum diabetes screening?

A comparison between point-of-care testing and venous glucose determination for the diagnosis of diabetes mellitus 6-12 weeks after gestational diabetes

Difference Between 2 H and 3 H 75 G Glucose Tolerance Test in the Diagnosis of Gestational Diabetes Mellitus (GDM): Results from a National Survey on Prevalence of GDM

The Utility of HbA1c for Screening Gestational Diabetes Mellitus and Its Relationship with Adverse Pregnancy Outcomes

Glycated Albumin in Screening the Abnormal Glucose Metabolism in Postpartum Women with Previous Gestational Diabetes Mellitus

Significance of glycosylated hemoglobin A1c and glycated albumin for the diagnosis of gestational diabetes mellitus

Clinical Significance of Glycosylated Hemoglobin Test in Gestational Diabetes Mellitus

Determination of the Contributing Factors and HbA1c Cutoff Leading to Glucose Tolerance Abnormalities Following Gestational Diabetes

Evaluation of point-of-care maternal glucose measurements for the diagnosis of gestational diabetes mellitus

Investigation of Glucohemoglobin in Gestational Diabetes Mellitus

Application of Glycated Hemoglobin in the Perinatal Period.

Intrapartum and Early Postpartum Glycemic Profiles in Women with Gestational Diabetes Mellitus: an Observational Study

The Prevalence of Postpartum Glucose Intolerance in Women with Gestational Diabetes

Clinical Significance of Glycosylated Hemoglobin in Screening Gestational Diabetes Mellitus

Performance of point-of-care glucose testing for the diagnosis of gestational diabetes in South Africa

The Diagnosis Value Of Blood Glucose Combined Glycosylated Hemoglobin In Gestational Diabetes

Evaluating the utility of a point-of-care glucometer for the diagnosis of gestational diabetes

Long-Term Postpartum Outcomes of Insulin Resistance and Β-Cell Function in Women with Previous Gestational Diabetes Mellitus.

Utilization of a Postpartum Fasting Blood Glucose to Predict Impaired Glucose Tolerance in Patients with Gestational Diabetes Mellitus

The diagnostic accuracy of HbA1c in detecting gestational diabetes mellitus among Chinese pregnant individuals